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 Abstract
Objective: Mounting evidence suggests that activation of complement, an important constituent of innate immunity, contributes to atherosclerosis.
Here we investigated the expression of complement components (CCs) in the setting of experimental and clinical hypercholesterolemia, a major risk
factor for atherosclerosis, their effects on vascular smooth muscle cell (VSMC) and macrophage proliferation, and the underlying molecular
mechanisms.
Methods: For this study we analyzed the mRNA and protein expression of several CCs in plasma and aorta of hypercholesterolemic
atherosclerosis-prone apolipoprotein E-null mice (apoE-KO) and in plasma of normocholesterolemic subjects and familial hypercholester-
olemia (FH) patients. We also carried out in vitro molecular studies to assess the role of CCs on the control of macrophage and VSMC
proliferation.
Results: Fat-fed apoE-KO mice experiencing severe hypercholesterolemia (∼400 mg/dL), but not fat-fed wild-type controls with plasma
cholesterol levelb110 mg/dL, displayed in aortic tissue upregulation of several CC mRNAs, including C3, C4, C1s, and C1q. In apoE-KO
mice, induction of C3 mRNAwas already apparent two days after fat feeding when hypercholesterolemia was manifested yet atherosclerotic
lesions were absent or incipient. Rapid C3 and C4 protein upregulation was also observed in the plasma of fat-fed apoE-KO mice, and FH
patients exhibited higher plasmatic C3a, C4 γ chain, C1s and C3c α chain protein levels than normocholesterolemic subjects. In vitro, C3 and
C3a, but not C3a-desArg, C4 and C1q, promoted macrophage and VSMC proliferation through Gi protein-dependent activation of
extracellular signal-regulated kinase 1/2 (ERK1/2). We also found that C3-enriched FH plasma evoked a stronger mitogenic response in
macrophages than normocholesterolemic plasma, and treatment with anti-C3 antibodies eliminated this difference.
Conclusions: Both experimental and clinical hypercholesterolemia coincides with a concerted activation of several CCs. However, only C3
and C3a elicited a mitogenic response in cultured VSMCs and macrophages through Gi protein-dependent ERK1/2 activation. Thus, excess⁎ Corresponding author. Instituto de Biomedicina de Valencia, Jaime Roig 11, 46010 Valencia, Spain. Tel.: +34 963391752; fax: +34 963391751.
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proliferation.
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 1. Introduction
Atherosclerosis is a complex inflammatory disease trig-
gered by several cardiovascular risk factors (e.g., hyperlip-
idemia, hypertension, obesity, diabetes, smoking), which
promote endothelial damage and neointimal accumulation of
various cell types (e.g. VSMCs, monocytes/macrophages,
T \cells and dendritic cells), and non-cellular material, such as
modified lipids and extracellular matrix components [1,2].
Circulating monocytes adhere to the injured endothelium,
undergo transendothelial migration and differentiate into
macrophages that avidly absorb modified low-density
lipoproteins (LDLs) and become lipid-laden foam cells.
Activated neointimal macrophages and lymphocytes produce
inflammatory mediators that induce their own proliferation,
as well as VSMC hyperplasia and migration towards the
growing atherosclerotic lesion [3].
The complement system, an important constituent of
innate immunity, consists of a complex group of serum
proteins and glycoproteins as well as soluble or membrane-
bound receptors, which mediate critical functions in
inflammation and in the body's defence against invading
microorganisms [4,5]. A cascade of serine proteases can be
activated by antibody/antigen complexes (classic comple-
ment pathway), by harmful substances such as zymosan
(alternative pathway), or by mannose-binding lectin (lectin
pathway). The three complement pathways converge in the
activation of the C3-convertase that ultimately mediates the
formation of the terminal membrane attack complex C5b-9
causing cell lysis and secretion of pro-inflammatory
molecules. In addition to its role in the recognition of foreign
antigens and pathogens, the complement system seems to
play an important role in immunoregulatory functions, in the
generation of tissue inflammatory reactions, and in the clean-
up and repair of tissues during ischemic, autoimmune and
inflammatory disorders (e.g., rheumatoid arthritis, asthma,
lupus nephritis, and atherosclerosis) [4–8]. Deposits of C5b-
9, a marker of in situ complement activation, have been found
to co-localize with macrophages within human atheroscle-
rotic lesions [9,10]. Subsequent studies have demonstrated
the local expression of various complement components
(CCs) in endothelial cells, VSMCs and dendritic cells from
advanced atherosclerotic plaques in humans [11–15] and
experimental animals [16–21]. Moreover, plasmatic levels of
CCs are elevated in coronary artery disease patients [22–25].
Whereas the aforementioned studies suggest a role to the
complement system in atherosclerosis, it remains controver-
sial whether the net effect of complement activation is pro- oranti-atherogenic [6]. Moreover, little is known regarding the
expression of CCs at the onset of atherosclerosis, and their
effects on VSMC and macrophage functions involved in the
growth of early atherosclerotic lesions (e.g. cell prolifera-
tion). In this study we examined the expression of CCs in
hypercholesterolemic atherosclerosis-prone apolipoprotein
E-null (apoE-KO) mice [26], and in patients with familial
hypercholesterolemia (FH), an autosomal dominant inherited
disorder featuring elevated plasma LDL-cholesterol levels
and premature coronary artery disease [27]. We also
investigated the effects of CCs on macrophage and VSMC
proliferation in culture, and the underlying signaling
pathways.
2. Methods
2.1. Animals and diets
The investigation conforms with theGuide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health. Male wild-type and apoE-KO mice
(C57BL/6J, Charles River) were maintained on a low-fat
standard diet (LF-diet, 2.8% fat, Panlab, Barcelona, Spain).
When indicated, 2–3-month-oldmice received for up to 30 days
a high-fat cholesterol-rich diet (HFC-diet, 12% fat, 1.25%
cholesterol, 0.5% sodium cholate, S8492-S010, Ssniff). Blood
was extracted through the retroorbital plexus and collected into
EDTA tubes to obtain plasma. Cholesterol was measured by
spectrometry (Chol-H-L-Type, Wako), and C3 and C4 by
turbidimetry (Alfa-Wassermann, Ref. P/N05760216).
2.2. Human studies
The investigation conforms with the principles outlined in
the Declaration of Helsinki. The studies included control
normolipidemic subjects recruited from family physicians lists
and hospital staff, and patients with a genetic confirmation of
FH (see Supplementarymaterial). All participants gavewritten
informed consent to a protocol approved by the local review
board. The exclusion criteria included acute infectious disease
in the previous week, active chronic inflammatory disease,
anti-inflammatory drugs consumption, including oral steroids
and non-steroidal anti-inflammatory drug in the previous
week, and serum C-reactive protein concentrationN10 mg/L.
Plasmatic lipid levels were determined as follows: (a)
cholesterol and triglycerides by standard enzymatic methods,
(b) HDL-cholesterol by precipitation with phosphotungstic
acid and magnesium chloride [28], (c) LDL-cholesterol was
Fig. 1. Increased expression of CCs in aortic tissue and plasma of fat-fed apoE-KO mice. Wild-type and apoE-KO mice fed with LF-diet or HFC-diet for the
indicated times were sacrificed to obtain aortic tissue and plasma. (A) CC mRNA levels in aortic tissue were determined by real-time RT-PCR. For each gene,
results are represented relative to the RNA level of mice receiving LF-diet (set as 1) (n=4–6 RNA samples obtained from aortic tissue pooled from 2–6 mice).
(B) Plasmatic levels of C3, C4 and total cholesterol (n=8–10). (C) Simple regression analysis of the data presented in panel B for discerning relationships
between plasmatic levels of cholesterol and CCs in apoE-KO mice. The F-test was used to measure the significance of the regression analysis.
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 estimated with the Friedewald equation [29], (d) apolipopro-
tein AI (apoAI) and B (apoB) using turbidimetric techniques,
(e) C3a by ELISA (BD Biosciences, ref. 550449).
2.3. Quantitative real-time reverse transcription-polymerase
chain reaction (real-time RT-PCR)
Total RNAwas extracted from frozen aortic tissue pooled
from 2–6 mice using TRIzol reagent (Invitrogen). DNase-treated RNA (1–2 μg) was reverse transcribed either with M-
MLV Reverse Transcriptase RNase H minus and Oligo
(dT)15 as primers (Promega), or with High-Capacity cDNA
reverse transcription kit with random hexamers (Applied
Biosystems). cDNA was amplified using assays-on-demand
kits containing primers, TaqMan probes and the TaqMan
universal PCR mix (Applied Biosystems). Reaction mixtures
without template served as negative controls. For template
input normalization, GAPDH or β-actin transcript levels
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 were measured to calculate the threshold cycle number (Ct).
Fold change values were calculated as the ratio of the ▵Ct
sample averages.
2.4. Cell culture
Murine RAW macrophages (RAW 264.7 TIB-71, Amer-
ican Type Culture Collection) were maintained in 10% FBS/
DMEM. Rat primary VSMCs were obtained from aortic
tissue as previously described [30] and maintained in 10%
FBS/DMEM F12. Starvation media for cell proliferation
studies contained 0.1% FBS.
When indicated, cells were treated with human CCs (C3,
Ref.204885; C3a, Ref.204881; C3a-desArg, Ref.204884;
C1q, Ref.204876; C1s, Ref. 204879; C4, Ref.204886;
Calbiochem). Cell proliferation and Western blot assays
are described in the Supplementary material.
2.5. Statistical analysis
All values are expressed as mean±SEM. Differences were
evaluated using either 2-tail, unpaired t-test (experiments
with 2 groups) or 1-way ANOVA and Bonferroni's post-hoc
test (experiments with ≥3 groups). The F-test, which uses
the sum of the squares and mean squares to calculate an F-
statistic and an associated p value, was used to measure the
significance of the regression analysis. Statistical signifi-
cance was taken at pb0.05.
3. Results
3.1. Increased expression of CCs in aortic tissue and plasma
of hypercholesterolemic apoE-KO mice
We first examined by real-time RT-PCR the expression of
CCs in the aorta of apoE-KO mice fed with LF-diet and
HFC-diet. C3 and C4 mRNA steady-state levels were
significantly increased at 2 and 7 days of HFC-diet,
respectively, and augmented expression of these CCs was
sustained for up to 30 days of fat feeding (Fig. 1A). Induction
of C1s and C1qγ mRNA was only observed in the aorta ofTable 1
Characteristics of control and FH patients
n Age
(years)
Weight
(kg)
Total cholesterol
(mg/dL)
HDL-chole
(mg/dL)
Control 19 29.8±3.0 69.5±2.9 188.4±6.0 44.1±2.5
Females 6 25.3±2.0 58.8±2.5 190.2±7.4 57.2±1.0
Males 13 31.9±4.3 74.4±3.3 187.5±8.2 38.1±1.8
FH patients 14 36.4±2.1 69.5±3.3 328.8±15.4 47.6±4.4
Females 8 34.8±3.3 64.8±5.1 312.5±20.1 56.5±5.4
Males 6 38.7±2.5 75.8±2.2 350.5±22.9 35.8±3.3
t-test (control
versus FH)
NS NS pb1×10−9 NS
NS: not significant (pN0.05).apoE-KO mice fed with HFC-diet for 30 days. We have
previously shown in apoE-KO mice absence of aortic
atheromas or presence of only incipient lesions after 2 and
7 days of HFC-diet, and formation of prominent lesions after
30 days of HFC-diet [31]. We also measured the levels of
plasmatic cholesterol and C3 and C4 proteins in apoE-KO
mice (Fig. 1B). All parameters reached maximum levels by
3 days of HFC-diet and were maintained up to 30 days of fat
feeding. Both C3 (pb0.04) and C4 (pb0.0007) protein
levels directly correlated with the level of circulating
cholesterol (Fig. 1C).
In contrast to the findings in apoE-KO mice, CC mRNA
expression was not elevated in the aorta of wild-type controls
fedwithHFC-diet for 7 and 30 days (Fig. 1A), which exhibited
a level of plasmatic cholesterol much lower than apoE-KO
mice fed with HFC-diet (b110 mg/dL versus ∼400 mg/dL,
respectively) (Fig. 1B).
3.2. Induction of complement components in the plasma of
FH patients
Having demonstrated that severe hypercholesterolemia in
apoE-KO mice is associated with CC upregulation, we
sought to analyze plasma samples from normocholester-
olemic subjects and FH patients. We found statistically
significant increases in total cholesterol, LDL-cholesterol
and apoB in FH patients compared with controls (Table 1).
Plasmas from 4 normocholesterolemic subjects and 8 FH
patients were simultaneously subjected to 2D-PAGE to
identify and quantify protein spots displaying differential
expression, as assessed using the PDQuest software. Protein
spots exhibiting reproducible differential expression were
excised from the gels, digested with trypsin and analyzed by
MS/MS (Fig. 2A). These analyses identified in FH patients
increased intensity of spots containing peptides from the C4
γ chain, C1s and the C-terminal fragment of the α chain of
C3b. Taken into account both the apparent molecular weight
and the pI of the respective spots in the 2D gel, we conclude
that these peptides upregulated in FH plasma represent C4 γ
chain, C1s and C3c α chain, respectively. Consistent with the
notion that C3-convertase cleaves C3 into C3a and C3b, westerol LDL-cholesterol
(mg/dL)
Triglycerides
(mg/dL)
apoB
(mg/dL)
apoAI
(mg/dL)
129,3±5.8 74.7±7.6 76.5±3.8 136.5±5.2
119,8±6.2 66.0±11.9 67.2±5.5 156.3±9.0
133,7±7.7 78.8±9.8 80.8±4.7 127.3±4.6
261,3±15,7 99.1±13.2 178.8±9.1 132.6±8.6
240,8±18,3 76.1±11.2 164.3±7.3 152.3±7.7
288,7±24.5 129.8±22.1 198.2±16.6 106.5±9.7
pb6×10−10 NS pb1×10−11 NS
Fig. 2. Increased levels of CCs in plasma of FH patients. (A) Left upper panel, 2D-electrophoretic separation of FH patient plasma indicating the positions of CC
spots whose volume was found to be increased in comparison to controls. Displayed are the MS/MS-derived amino acid sequences of the tryptic peptide ions that
served to identify the proteins listed at the right. Panels C1s, C3, and C4 show close-up views of equally-labeled regions in the 2D-gel and illustrate the
differential expression levels of CC bands in controls and FH patients from both sexes. The graphs represent the fold induction in FH patients (4 females/4 males)
relative to average control levels (2 females/2 males) (set as 1). (B) Plasmatic C3a levels determined by ELISA in control subjects (14 females) and FH patients
(8 females/6 males). (C) Simple regression analysis of the data presented in panel B for discerning relationships between plasmatic levels of cholesterol and C3a.
The F-test was used to measure the significance of the regression analysis.
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Fig. 3. Effect of CCs on the proliferation of primary VSMCs (A–E) and RAWmacrophages (F–J). (A–D, F–I). Confluent cells were serum-starved for 48 h and
then stimulated for 24 h with CCs. In B and G, the amount of C3a and C3a-desArg was 0.01 μM. De novo DNA synthesis was assessed as 3H-thymidine
incorporation (n=3–4 experiments). Results are shown relative to unstimulated cells (set as 100%). Comparisons versus unstimulated cells: ⁎pb0.05; ⁎⁎pb0.01;
⁎⁎⁎pb0.001. Comparisons versus C3a-desArg: †pb0.01; ††pb0.001. (E, J) MTTassay-based growth curves of cells incubated for different times in DMEM F12
media supplemented with 1 μMC3 (black squares) or 1 μM C1q (white squares). The values obtained in control cells incubated with PBS were subtracted from
those of CC-treated cells. Comparisons versus t=0 (same treatment): ⁎pb0.0004; ⁎⁎pb0.0001. Comparisons C3 versus C1q (same time point): †pb0.0025;
††pb0.0001. The discontinuous lines show the p value for other relevant comparisons.
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 also observed by ELISA a significant increase in C3a level in
FH plasma compared with normocholesterolemic controls
(514 ng/mL versus 327 ng/mL, respectively, pb0.01; n=14)
(Fig. 2B). As in the apoE-KO mouse model (Fig. 1C), we
found a significant direct correlation between plasma
cholesterol and C3a level in controls and FH patients, as
revealed by regression analysis (pb0.05) (Fig. 2C).3.3. C3 andC3a, but not C1q orC4, induce the proliferation of
cultured VSMCs and macrophages via Gi protein-dependent
ERK activation
We next performed [3H]-thymidine incorporation assays
to examine the effect of CCs on the proliferation of murine
RAW macrophages and primary rat VSMCs. Increasing
Fig. 4. ERK1/2 activation is required for C3a-induced RAW and VSMC proliferation. When indicated, CCs were added to culture plates at 0.01 μM (C3, C3a,
C3a-desArg) and 1 μM (C1q) and cells were pre-incubated with PD98059 (5 μmol/L, 1 h), PTX (0.5 μg/mL, overnight) or U0126 (10 μmol/L, 1 h) prior to
addition of CCs. Western blots are representative of 2–3 experiments. The results of 3H-thymidine incorporation assays are shown relative to controls (=100%)
and represent the mean±SEM of 3–4 experiments. Confluent RAW macrophages (A, C) and VSMCs (B, D) were serum-starved for 48 h and left untreated
(control) or incubated with CCs (2, 20 and 60 min in A and B; 20 min in C and D). Cell lysates were analyzed by Western blot with antibodies against total and
phosphorylated (active) ERK1/2 (ERK1/2 and p-ERK1/2, respectively). (E, F) 3H-thymidine incorporation and Western blot of serum-starved confluent RAW
macrophages stimulated for 24 h (E) or 20 min (F) with C3a, with or without PTX or PD98059. (G) Effect of U0126 on 3H-thymidine incorporation in starvation-
synchronized VSMCs stimulated for 24 h with C3 or C3a.
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 doses of C3, C3a, C4 and C1q were added to starvation-
synchronized cultures. C3 up to 1 μM and C3a up to 0.1 μM
elicited a dose-dependent mitogenic response in VSMCs
(Fig. 3A) and macrophages (Fig. 3F). In contrast, acylation
stimulating protein/C3a-desArg, a desarginated form of C3a
which is unable to bind to the C3a receptor (C3aR) [32],
failed to induce de novo DNA synthesis in these cell types
(Fig. 3B,G). Likewise, the members of the classic comple-
ment pathway C4 and C1q did not induce VSMC andmacrophage proliferation at concentrations up to 10 μM
(Fig. 3C,D,H,I). Using the cell growth MTT-based assay, we
confirmed the growth promoting activity of C3, but not of
C1q, on VSMCs (Fig. 3E) and RAW macrophages (Fig. 3J).
None of the CCs tested in the proliferation assays affected
the uptake of acetylated LDLs by RAW macrophages (data
not shown).
Induction of themitogen-activated protein kinase (MAPK)/
extracellular signal-regulated kinase (ERK) pathway plays a
347F. Verdeguer et al. / Cardiovascular Research 76 (2007) 340–350pivotal role in transducing signals required for cell prolifer-
ation [33]. Treatment of serum-starved RAW macrophages
(Fig. 4A) and VSMCs (Fig. 4B) with C3a induced a rapid
activation of the ERK isoforms of 44 and 42 kDa (ERK1 and
ERK2, respectively), as revealed by Western blot using an
antibody specific for their phosphorylated (active) forms (p-
ERK1/2). This increase in phosphorylated ERK1/2 occurred
without concomitant changes in total ERK1/2 protein
expression. Neither C3a-desArg (Fig. 4C) nor C1q (Fig. 4D)
caused ERK1/2 phosphorylation.
We next investigated whether ERK1/2 activation was
required for C3/C3a-dependent cell proliferation. Pre-
incubation of RAW macrophages with the MEK inhibitor
PD98059 abrogated C3a-dependent ERK1/2 phosphoryla-
tion coinciding with a significant reduction in 3H-thymidine
incorporation (Fig. 4E,F). Similar results were obtained
when these cultures were pre-treated with PTX, an inhibitorFig. 5. C3 contributes to the increased mitogenic activity of plasma from FH
patients. RAW macrophages were serum-starved for 48 h and then re-
stimulated for 20 h with 3% human plasma. Cells were pulse-labeled with
3H-thymidine for the last 4 h and harvested to estimate de novo DNA
synthesis. Results are represented relative to 3H-thymidine incorporation in
untreated cells (set as 100%). (A) Mitogenic activity was assayed in
untreated cells (n=10) and in cells incubated with plasma from 10 controls
and 10 FH patients. (B) Mitogenic activity was assayed in untreated cells
(n=4) and in cells incubated with the supernatant of control or FH plasma
obtained after immunoprecipitation with either anti-C3 IgG or control IgG
(n=4 independent pools obtained by mixing plasma from either 5 control
subjects or 5 FH patients).
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 of signaling mediated by heterotrimeric G proteins of the Gi
subfamily (Fig. 4E,F). PD98059 also blunted ERK1/2
phosphorylation and proliferation in starvation-synchronized
VSMCs treated with 1 μM C3 (data not shown), and the
MEK inhibitor U0126 reduced 3H-thymidine incorporation
in VSMCs exposed to C3 and C3a (Fig. 4G). Collectively,
these results suggest that ERK1/2 activation via Gi protein-
dependent signaling is necessary for full C3/C3a mitogenic
activity in macrophages and VSMCs.
3.4. C3 contributes to the increased mitogenic activity of
plasma from FH patients
We sought to compare the mitogenic activity of control
and FH plasma. Starvation-synchronized RAWmacrophages
were incubated for 14 h with DMEM containing 3% control
or FH plasma. Treatment with either control or FH plasma
significantly increased proliferation compared to untreated
cells (pb0.001, n=10), although the mitogenic effect of FH
plasma was higher (pb0.001 versus control plasma)
(Fig. 5A). To evaluate whether C3 might contribute to the
observed differential response, we immunoprecipitated
control and FH plasma with anti-C3 IgG or control IgG
and employed the resulting supernatant to carry out [3H]
thymidine incorporation assays. In agreement with the
results in Fig. 5A, both control and FH plasmas immuno-
precipitated with control IgG induced cell proliferation
compared with untreated cells (pb0.001), and this response
was stronger for FH plasma (pb0.01 versus control plasma)
(Fig. 5B). Notably, whereas anti-C3 IgG did not affect the
mitogenic activity of control plasma, cell proliferation
induced by anti-C3-treated FH plasma was significantly
reduced (Fig. 5B).
4. Discussion
Whilst studies in animals and humans have demonstrated
the upregulation of various CCs within advanced atheroscle-
rotic lesions (see Introduction), studies in complement-
deficient animals have yielded confusing results regarding
the possible role on atherosclerosis of these proteins. In
rabbits, C6 deficiency protected against diet-induced athero-
sclerosis without affecting plasma cholesterol levels and
lipoprotein profiles [34]. However, atherosclerosis was
similar in C5-deficient and C5-competent apoE-KO mice
[35]. Likewise, serum lipid content and lesion size were
comparable in LDLR-KO mice lacking C3, although
immunohistological studies suggested that intact C3 may
be necessary for atheroma maturation beyond the foam cell-
rich stage [19]. It is noteworthy that C3 absence increased
diet-induced hyperlipemia and atherosclerosis in the more
atherogenic apoE/LDLR doubly deficient mouse model [17].
Very recently, Bhatia et al. [36] reported an augmented
atherosclerosis in C1qa/LDLR doubly deficient mice com-
pared with LDLR-KO mice, suggesting a protective role of
C1qa against atherosclerosis. These seemingly conflicting
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 results may reflect the complexity of the complement system,
which comprises approximately 30 factors that may play
partially redundant and/or opposite roles on cellular process-
es involved in atherosclerosis [6]. Since previous animal and
human studies have focused on the analysis of advanced
atheromas, the present study was undertaken to investigate
the expression of CCs in atherosclerosis-prone apoE-KO
mice fed with LF-diet and receiving HFC-diet for short (2–
7 days) and long (30 days) periods, which caused comparable
hypercholesterolemia. Using the same animal model, we
previously found prominent aortic atheromas at 30 days of
HFC-diet, but lesions were absent or just incipient after 2–
7 days under this dietary regimen [31]. At all time points
examined here (3–30 days HFC-diet), we found augmented
C3 and C4 protein expression in the plasma of apoE-KOmice
experiencing severe hypercholesterolemia (∼400 mg/dL).
Likewise, aortic expression of C3, C4, C1q and C1s mRNA
expression was elevated at 30 days of HFC-diet. Notably,
aortic upregulation of C3 and C4 mRNA steady-state level
was already evident after 2 and 7 days of HFC-diet,
respectively. In contrast, aortic CC mRNA expression was
not elevated in fat-fed wild-type mice, which maintained a
plasma cholesterol levelb110 mg/dL even after 30 days of
HFC-diet. Thus, only when associated with hypercholester-
olemia, fat feeding produces in murine plasma and aorta a
rapid upregulation of CCs which precedes atheroma
formation and is sustained at later disease stages featuring
prominent atherosclerotic lesions.
Consistent with our findings in hypercholesterolemic
apoE-KO mice, we found increased plasmatic levels of
human C3a, C4 γ chain, C1s and C3c α chain proteins in FH
patients compared with normocholesterolemic subjects.
High plasmatic C3 and C4 levels have been reported in
individuals with primary hypercholesterolemia [37], and in-
creased circulating level of C5b-9, a clear indicator of
complement activation, is associated with human dyslipide-
mias, including hypercholesterolemia, hypertriglyceridemia
and low HDL-cholesterol level [38]. These findings are
consistent with the observation that cholesterol, modified
LDLs, and chylomicrons represent complement-activating
lipids [6,7,39,40].
We found that C3 and C3a, but not C3a-desArg, C4 and
C1q, induced in vitro macrophage and VSMC proliferation,
a key event in early stages of atheroma development [3]. The
C3aR is a member of the G-protein-coupled receptor family
[41]. Many biological responses of C3a can be blocked by
PTX, suggesting that C3aR is coupled to Gi proteins [42,43].
However, C3aR is coupled to both PTX-sensitive Giα and
PTX-insensitive Gα16 in leukocytes [44], and C3aR
activation in endothelial cell is sensitive to Rho inhibitors,
implying that this receptor can signal through distinct G
proteins in different cell types [45]. Recently it was reported
that C3aR-dependent signaling leads to PTEN activation in
both intrinsic renal cells and extrinsic inflammatory cells
[46]. Our studies in macrophages and VSMCs demonstrate
C3/C3a-dependent activation of ERK1/2, a signalingpathway required for cell proliferation induced by numerous
mitogens [33]. Moreover, blockade of ERK1/2 activation by
treatment with PTX, PD98059 or U0126 blunted de novo
DNA synthesis in cells exposed to C3/C3a. Previous studies
in human vein endothelial cells have shown ERK1/2
activation by C3a and C5a [42], and C5b-9-dependent
proliferation of human aortic endothelial and smooth muscle
cells [47,48]. Moreover, C3 may contribute to the exagger-
ated growth of VSMCs from spontaneously hypertensive
rats at an age preceding significant increases in blood
pressure [49]. Thus, rapid complement activation within the
artery wall may contribute, at least in part through Gi
protein-dependent ERK1/2 activation, to abnormal cell
proliferation at the onset of atherosclerosis and hypertension.
Our observation that, compared with normocholesterolemic
plasma, C3-enriched FH plasma elicited a stronger mito-
genic response in macrophages and that this difference was
abolished upon addition of anti-C3 antibodies to the plasma,
suggests that high circulating C3 level in FH patients may
contribute to atherosclerosis by facilitating neointimal cell
proliferation. However, additional studies are required to test
this possibility. C3a and C5a evoke chemoattraction of
leukocytes [50–52], suggesting an additional mechanism by
which CCs may promote atheroma growth.
In conclusion, the present study demonstrates that severe
hypercholesterolemia is associated with a concerted upregu-
lation of CCs in the plasma and aorta of fat-fed apoE-KO
mice and in the plasma of FH patients. Our in vitro findings
suggest, however, that different CCs play distinct roles on
cellular processes involved in atheroma formation, since C3
and C3a, but not C1q and C4, promoted VSMC and
macrophage proliferation via Gi protein-dependent ERK
activation. We found that C3 induction in aorta and plasma of
fat-fed apoE-KO mice occurs at early stages of hypercholes-
terolemia preceding atheroma formation. Thus, given the
evidences presented here suggesting that C3 contributes to
the mitogenic activity of FH plasma, we propose that chronic
elevation of plasma C3/C3a level in dyslipidemic subjects
may contribute to atheroma development by inducing
neointimal cell proliferation.
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